Nabriva Therapeutics (NASDAQ:NBRV) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.

Nabriva Therapeutics Price Performance

The company has a market capitalization of $45.46 million, a PE ratio of -0.07 and a beta of 1.53. The company has a current ratio of 0.85, a quick ratio of 0.52 and a debt-to-equity ratio of 0.12. Nabriva Therapeutics has a one year low of $1.22 and a one year high of $8.45. The business has a fifty day simple moving average of $0.14 and a two-hundred day simple moving average of $0.61.

Institutional Trading of Nabriva Therapeutics

An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC boosted its holdings in Nabriva Therapeutics plc (NASDAQ:NBRV) by 102.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 795,938 shares of the biotechnology company’s stock after acquiring an additional 402,144 shares during the quarter. Renaissance Technologies LLC owned 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent quarter. Institutional investors and hedge funds own 0.27% of the company’s stock.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.